Biomarker assessment and genetic screening help contextualize why some patients achieve results at lower doses while others require escalation
Current projections look at a potential 2028 launch, contingent on further clinical results and regulatory approvals
Unlike other approved GLP-1 medications, Wegovy and Zepbound, which also target the gut hormone GLP-1, retatrutide targets three receptors known to regulate appetiteGLP-1, glucagon and glucose-dependent insulinotropic polypeptide (GIP)
The most well-known GLP-1 receptor agonists include semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)
For states like Mississippi, West Virginia, and Arkansas, annual GLP-1 costs at commonly prescribed injectable prices can still represent more than 12% of median per capita income, roughly double the national average
AND Final approval of the version to be published
.png)
